These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26553682)

  • 41. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial.
    Macias Parra M; Gentile A; Vazquez Narvaez JA; Capdevila A; Minguez A; Carrascal M; Willemsen A; Bhusal C; Toneatto D
    Vaccine; 2018 Nov; 36(50):7609-7617. PubMed ID: 30414782
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt.
    ; Altmann D; Aseffa A; Bash M; Basta N; Borrow R; Broome C; Caugant D; Clark T; Collard JM; Djingarey M; Goldblatt D; Greenwood B; Griffiths U; Hajjeh R; Hassan-King M; Hugonnet S; Kimball AM; LaForce M; MacLennan C; Maiden MC; Manigart O; Mayer L; Messonnier N; Moisi J; Moore K; Moto DD; Mueller J; Nascimento M; Obaro S; Ouedraogo R; Page AL; Perea W; Pluschke G; Preziosi MP; Sow S; Stephens D; Stuart J; Thomson M; Tiendrebeogo S; Trape JF; Vernet G
    Vaccine; 2013 Mar; 31(11):1453-7. PubMed ID: 23273967
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Evaluation of safety of meningococcal group AC bivalent polysaccharide conjugate vaccine in children aged 5-24 months old].
    Zhou H; Wang JY; Tan Y; Lü HY; Wang M; Cai QC; Zhang HZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Oct; 47(10):920-3. PubMed ID: 24378132
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Study on immunogenicity of group A and group C meningococcal conjugate vaccine with coupling group B meningococcal outer membrane protein].
    Ma FB; Tao H; Wang HJ
    Zhongguo Yi Miao He Mian Yi; 2009 Oct; 15(5):451-5. PubMed ID: 20084975
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
    Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
    Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM).
    Frasch CE; Preziosi MP; LaForce FM
    Hum Vaccin Immunother; 2012 Jun; 8(6):715-24. PubMed ID: 22495119
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults.
    Aplasca-De Los Reyes MR; Dimaano E; Macalalad N; Dbaibo G; Bianco V; Baine Y; Miller J
    Hum Vaccin Immunother; 2012 Jul; 8(7):881-7. PubMed ID: 22485048
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Response thresholds for epidemic meningitis in sub-Saharan Africa following the introduction of MenAfriVac®.
    Trotter CL; Cibrelus L; Fernandez K; Lingani C; Ronveaux O; Stuart JM
    Vaccine; 2015 Nov; 33(46):6212-7. PubMed ID: 26463444
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
    Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
    Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Technical Development of a New Meningococcal Conjugate Vaccine.
    Frasch CE; Kapre SV; Lee CH; Préaud JM
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S404-9. PubMed ID: 26553667
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults.
    Bermal N; Huang LM; Dubey AP; Jain H; Bavdekar A; Lin TY; Bianco V; Baine Y; Miller JM
    Hum Vaccin; 2011 Feb; 7(2):239-47. PubMed ID: 21343698
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.
    Quiambao BP; Jain H; Bavdekar A; Dubey AP; Kolhe D; Bianco V; Van der Wielen M; Miller JM
    Hum Vaccin Immunother; 2016 Aug; 12(8):2162-2168. PubMed ID: 27152501
    [TBL] [Abstract][Full Text] [Related]  

  • 53. One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children.
    Klein NP; Baine Y; Bianco V; Lestrate PR; Naz A; Blatter M; Friedland LR; Miller JM
    Pediatr Infect Dis J; 2013 Jul; 32(7):760-7. PubMed ID: 23348814
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Vaccine Meets Its Promise: Success in Controlling Epidemic Meningitis in Sub-Saharan Africa.
    Sambo L; Chan M; Davis S; Lake A; Berkley S; Poonawalla C; Elias CJ
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S387-8. PubMed ID: 26553663
    [No Abstract]   [Full Text] [Related]  

  • 55. Documenting the Results of a Successful Partnership: A New Meningococcal Vaccine for Africa.
    Okwo-Bele JM; LaForce FM; Borrow R; Preziosi MP
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S389-90. PubMed ID: 26553664
    [No Abstract]   [Full Text] [Related]  

  • 56. An Update on Meningococcal Vaccination.
    Garland JM
    R I Med J (2013); 2020 Aug; 103(6):41-43. PubMed ID: 32752565
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A field based evaluation of adverse events following MenAfriVac® vaccine delivered in a controlled temperature chain (CTC) approach in Benin.
    Steffen C; Tokplonou E; Jaillard P; Dia R; Alladji MN; Gessner B
    Pan Afr Med J; 2014; 18():344. PubMed ID: 25574320
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution.
    Marc LaForce F; Ravenscroft N; Djingarey M; Viviani S
    Vaccine; 2009 Jun; 27 Suppl 2():B13-9. PubMed ID: 19477559
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali.
    Roy Chowdhury P; Meier C; Laraway H; Tang Y; Hodgson A; Sow SO; Enwere GC; Plikaytis BD; Kulkarni PS; Preziosi MP; Niedrig M
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S586-93. PubMed ID: 26553692
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
    Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
    Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.